GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Plus Therapeutics Inc.
Plus Therapeutics, an oncology company developing radiotherapeutic drugs, is a venture-backed bet on its technology. Its price is highly volatile and depends not on revenue, but on clinical trial results and investor confidence in the breakthrough potential of its platform.
Share prices of companies in the market segment - Breast cancer
Plus Therapeutics develops radiotherapy drugs for the treatment of difficult-to-treat cancers, such as recurrent glioblastoma. We've categorized it under "Breast Cancer." The chart below shows how investors view the targeted radiotherapy sector in oncology.
Broad Market Index - GURU.Markets
Plus Therapeutics develops radiotherapy drugs for the treatment of difficult-to-treat cancers, such as recurrent glioblastoma. As a component of the GURU.Markets index, it represents the targeted radiotherapy sector. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
PSTV - Daily change in the company's share price Plus Therapeutics Inc.
Plus Therapeutics, Inc.'s daily stock price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its radiotherapy drugs for cancer treatment.
Daily change in the price of a set of shares in a market segment - Breast cancer
Plus Therapeutics, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with the dynamics of PSTV, which depends on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Plus Therapeutics is a biotech company developing radiation therapy for cancer treatment. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Plus Therapeutics Inc.
Plus Therapeutics, Inc.'s year-over-year performance is a story about the development of targeted radiotherapy. Its 12-month market cap is entirely dependent on clinical trial data for its lead drug, which delivers a high dose of radiation directly to brain tumors. Success could lead to a breakthrough in the treatment of this deadly disease.
Annual dynamics of market capitalization of the market segment - Breast cancer
Plus Therapeutics, Inc. is a clinical-stage biotechnology company developing radiation therapy for cancer. Its stock price is entirely dependent on clinical trial results and regulatory decisions. The chart reflects the high risks and potential for breakthroughs in this complex field.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Plus Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Plus Therapeutics Inc.
Plus Therapeutics develops radiotherapeutic drugs for the treatment of cancer. Its monthly growth is entirely dependent on progress in its clinical trials. Data from its leading glioblastoma treatment program, presented at conferences, is a key driver.
Monthly dynamics of market capitalization of the market segment - Breast cancer
Plus Therapeutics develops radiotherapeutic drugs for the treatment of cancer, including brain and breast tumors. This cutting-edge oncology sector has attracted considerable attention. The chart below reflects the investor willingness to invest in complex but potentially breakthrough treatments, and how their faith in this technology has evolved.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Plus Therapeutics develops radiotherapeutic drugs for the treatment of cancer. It is a high-tech oncology company in the clinical stage. Its stock performance depends entirely on the results of trials of its innovative approach, where every patient and every scan can determine the company's fate.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Plus Therapeutics Inc.
Plus Therapeutics develops innovative radionuclide therapy for cancer treatment. The company's stock price has been highly volatile this week, as investors are keenly anticipating any clinical trial data that could determine the future of its technology, particularly in the treatment of hard-to-treat tumors.
Weekly dynamics of market capitalization of the market segment - Breast cancer
Plus Therapeutics develops innovative radionuclide therapy for cancer treatment. The company's stock price has been highly volatile this week, as investors are keenly anticipating any clinical trial data that could determine the future of its technology, particularly in the treatment of hard-to-treat tumors.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Plus Therapeutics, a biotech company, lives in a world of its own. Its performance is driven by clinical trial data. A chart comparing the stock to the S&P 500 clearly demonstrates how its stock can rise or fall, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
PSTV - Market capitalization of the company Plus Therapeutics Inc.
Plus Therapeutics' market capitalization chart tells the story of developing an innovative treatment for recurrent glioblastoma, an aggressive form of brain cancer. The company uses a radionuclide delivered directly to the tumor. Its speculative chart reflects investor hopes for clinical trial data that could change the prognosis for patients.
PSTV - Share of the company's market capitalization Plus Therapeutics Inc. within the market segment - Breast cancer
Plus Therapeutics develops radiotherapeutic drugs for the treatment of difficult-to-treat cancers. Its share of the oncology segment's market capitalization reflects the potential of its unique radiation delivery technology. The chart below shows the volatility of its valuation, which depends on the results of clinical trials.
Market capitalization of the market segment - Breast cancer
Plus Therapeutics develops radiotherapeutic drugs for the treatment of difficult-to-treat cancers, such as glioblastoma. The chart below shows the overall market capitalization of the breast cancer treatment sector. It illustrates innovative approaches that can offer new hope to patients with the most aggressive tumors.
Market capitalization of all companies included in a broad market index - GURU.Markets
This shows a high-precision attack on cancer. Plus Therapeutics develops radiotherapeutic agents that deliver radiation directly to the tumor. The line on the graph represents its bet on this innovative treatment method, which promises to be more effective and less toxic than traditional radiation therapy.
Book value capitalization of the company, segment and market as a whole
PSTV - Book value capitalization of the company Plus Therapeutics Inc.
Plus Therapeutics' capital comes from its financial reserves and intellectual property for radionuclide therapy for recurrent glioblastoma. This represents focused scientific capital for the fight against aggressive cancer. The chart below shows how the biotech company manages its research budget to advance its innovative technology.
PSTV - Share of the company's book capitalization Plus Therapeutics Inc. within the market segment - Breast cancer
Plus Therapeutics develops radiotherapeutic drugs for cancer treatment. Its unique assets include manufacturing facilities capable of handling radioactive isotopes. The chart shows the company's share of this highly specialized and complex physical infrastructure.
Market segment balance sheet capitalization - Breast cancer
Radiopharmaceuticals, as the BCap_Seg chart shows, is a capital-intensive niche in biotech. Plus Therapeutics, which develops drugs using radioisotopes, requires specialized laboratories and manufacturing facilities that meet strict radiation safety standards.
Book value of all companies included in the broad market index - GURU.Markets
Plus Therapeutics' book value represents capital for the development of radiotherapeutic drugs delivered directly to tumors. It represents the financial basis for the creation of innovative treatments that use physical isotopes to specifically destroy cancer cells.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Plus Therapeutics Inc.
Plus Therapeutics develops radiotherapeutic drugs for cancer treatment. Its balance sheet is funded by research. Its market capitalization is a bet on a unique method of delivering radiation directly to tumors. The MvsBCap chart will reflect progress in clinical trials of this high-tech and risky therapy.
Market to book capitalization ratio in a market segment - Breast cancer
Plus Therapeutics develops radiotherapeutic drugs for the treatment of cancer. The company's value depends almost entirely on the success of its clinical trials. The chart reflects investor appreciation for its innovative approach to targeted radiation delivery to tumors.
Market to book capitalization ratio for the market as a whole
Plus Therapeutics develops radiotherapeutic drugs for the treatment of cancer. This is a cutting-edge technology that requires significant investment in R&D. The company's market value reflects investors' confidence in the success of this technology in clinical trials, rather than its current tangible assets.
Debts of the company, segment and market as a whole
PSTV - Company debts Plus Therapeutics Inc.
Plus Therapeutics, a clinical-stage oncology company developing radiotherapeutic drugs, is devoting all of its capital to funding R&D and trials. This cutting-edge treatment requires specific and expensive components and procedures. This chart shows how the company manages its resources during the long journey to approval and commercialization.
Market segment debts - Breast cancer
Plus Therapeutics develops radiotherapeutic drugs for the treatment of difficult-to-treat cancers, such as brain cancer. Radiopharmaceuticals are a complex and capital-intensive field. This chart shows how the company raises funds to finance its unique and expensive clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Plus Therapeutics Inc.
Plus Therapeutics focuses on treating cancer, particularly breast cancer, using radiation therapy technologies. This chart shows how much the company relies on debt to fund its cutting-edge research. High debt is an inevitable part of biotech, but it also creates enormous risks if the technology doesn't prove effective.
Market segment debt to market segment book capitalization - Breast cancer
Plus Therapeutics develops radiotherapeutic drugs for the treatment of cancer, particularly brain tumors. This chart shows the debt burden in the oncology biotech sector. It allows one to assess how the company finances its high-tech and risky clinical research compared to other players in this cutting-edge field.
Debt to book value of all companies in the market
Plus Therapeutics develops radiotherapeutic drugs for the treatment of cancer, particularly breast cancer. This chart, illustrating the overall financial health of the market, is critical for the biotech sector. The availability of capital for costly clinical trials is directly dependent on macroeconomic stability and investor risk appetite.
P/E of the company, segment and market as a whole
P/E - Plus Therapeutics Inc.
For Plus Therapeutics, a company developing radiotherapeutic drugs, this chart reflects investor hopes for a new approach to cancer treatment. Its valuation is based on the potential of its technology to deliver radiation directly to tumors, which could significantly improve treatment effectiveness and transform the company's fortunes.
P/E of the market segment - Breast cancer
This chart shows the average price-to-earnings ratio for the biotech sector, where Plus Therapeutics develops radiotherapy. The industry's high valuation reflects hopes for breakthroughs in oncology. The chart illustrates this general backdrop against which the potential of Plus Therapeutics' innovative technology is assessed.
P/E of the market as a whole
Plus Therapeutics develops radiotherapeutic drugs for the treatment of difficult-to-treat cancers, such as brain cancer. The company's technology delivers high doses of radiation directly to the tumor. This chart shows the risk appetite in biotech. It helps understand whether the market believes in the potential of this high-risk but potentially breakthrough technology and how its valuation is responding to clinical data.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Plus Therapeutics Inc.
Plus Therapeutics develops radiotherapeutic drugs for the treatment of cancer, particularly breast cancer. The company's technology delivers radiation directly to the tumor. This graph reflects analysts' confidence that clinical trials will demonstrate the efficacy and safety of this innovative approach to oncology treatment.
%20P%2FE%20Plus%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Plus-Therapeutics-Inc.&v=1772604260448 "Chart of the company's future (projected) P/E Plus Therapeutics Inc.")
Future (projected) P/E of the market segment - Breast cancer
Plus Therapeutics develops radiotherapy drugs for the treatment of difficult-to-treat cancers such as glioblastoma. This chart shows its future profitability expectations, allowing us to assess how highly the market values its innovative approach to delivering radiation directly to tumors while minimizing damage to healthy tissue.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Breast%20cancer&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Breast-cancer&v=1772604260466 "Future (projected) P/E graph of the market segment - Breast cancer")
Future (projected) P/E of the market as a whole
Plus Therapeutics develops radiotherapeutic drugs for cancer treatment. This is a cutting-edge but capital-intensive field. This schedule, reflecting investors' willingness to invest in the future, is critical for the company. During periods of market optimism, funding for the breakthrough oncology research Plus Therapeutics is pursuing becomes more accessible.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772604260506 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Plus Therapeutics Inc.
Plus Therapeutics, Inc. develops radiotherapeutic drugs for the treatment of cancer, particularly brain tumors. Its financial position is based on investments in clinical trials. This chart illustrates the capital burn required to advance its innovative technology, which delivers radiation directly to tumors while minimizing harm to healthy tissue.
Profit of companies in the market segment - Breast cancer
Plus Therapeutics develops radiotherapeutic agents for the treatment of difficult-to-treat cancers such as glioblastoma. Its technology uses nanoparticles to deliver radiation directly to the tumor. This graph reflects the high-risk and high-potential nature of the oncology sector, where innovative delivery methods can significantly improve treatment effectiveness.
Overall market profit
Plus Therapeutics develops radiotherapeutic drugs for cancer treatment. This is a cutting-edge and expensive area of medicine. The overall economic backdrop illustrated by this chart influences the amount of funding available for both scientific research and healthcare systems to finance such innovative treatments.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Plus Therapeutics Inc.
Plus Therapeutics develops innovative cancer treatments using radiotherapeutic agents delivered directly to tumors. This chart summarizes analyst forecasts, reflecting the success of clinical trials of this cutting-edge technology and its potential to treat hard-to-treat tumors.
%20profit%20of%20the%20company%20Plus%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Plus-Therapeutics-Inc.&v=1772604260711 "Graph of future (projected) profit of the company Plus Therapeutics Inc.")
Future (predicted) profit of companies in the market segment - Breast cancer
Plus Therapeutics develops targeted radiation therapy for the treatment of difficult-to-treat cancers such as glioblastoma. The company's technology delivers high doses of radiation directly to the tumor, minimizing damage to healthy tissue. This chart shows profitability projections for the biotech sector, reflecting hopes for a breakthrough in the treatment of the most aggressive forms of cancer.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Breast%20cancer&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Breast-cancer&v=1772604260763 "Graph of future (predicted) profits of companies in a market segment - Breast cancer")
Future (predicted) profit of the market as a whole
Plus Therapeutics develops radiotherapeutic drugs for cancer treatment. This area requires significant investment in research and development. The overall profit forecast shown in this chart shapes the investment climate and influences investor willingness to invest in biotech companies with long payback cycles and high risk.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772604260831 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Plus Therapeutics Inc.
Plus Therapeutics develops radiotherapeutic drugs. For a company in this cutting-edge field, the chart shows its estimated potential. Its high market value, coupled with modest revenue, reflects investor hopes that its technology will become a new standard in cancer treatment.
P/S market segment - Breast cancer
Plus Therapeutics, Inc. develops radiotherapeutic drugs for the treatment of difficult-to-treat cancers, such as brain cancer. This chart shows the average revenue estimate in the biotech sector. It helps us understand the premium investors place on the potential of the company's innovative platform to improve cancer treatment outcomes.
P/S of the market as a whole
Plus Therapeutics develops targeted radiation therapy for difficult-to-treat cancers, such as recurrent glioblastoma. Their method delivers high doses of radiation directly to the tumor. This chart, showing valuations of companies with actual revenues, highlights the enormous expectations investors have for breakthrough cancer treatments.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Plus Therapeutics Inc.
Plus Therapeutics develops radiotherapeutic drugs for the treatment of difficult-to-treat cancers, such as brain cancer. This chart reflects investors' confidence in the potential of its technology. The valuation is based on future revenues that could be generated if clinical trials are successful and its targeted radiation therapy methods are approved.
%20P%2FS%20Plus%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Plus-Therapeutics-Inc.&v=1772604260914 "The graph of the company's future (projected) P/S Plus Therapeutics Inc.")
Future (projected) P/S of the market segment - Breast cancer
Plus Therapeutics develops radiotherapy drugs for the treatment of difficult-to-treat cancers, such as brain cancer. Its technology delivers radiation directly to the tumor. This chart shows how the market views this innovative approach and its future potential compared to the oncology sector.
%20P%2FS%20market%20segment%20graph%20-%20Breast%20cancer&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Breast-cancer&v=1772604260934 "Future (projected) P/S market segment graph - Breast cancer")
Future (projected) P/S of the market as a whole
Plus Therapeutics develops radiotherapeutic drugs for the treatment of cancer, particularly breast cancer. This chart, reflecting investors' risk appetite, directly impacts the company's ability to finance its operations. During periods of market optimism, investors are more inclined to invest in biotech companies with innovative but high-risk approaches.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772604260986 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Plus Therapeutics Inc.
Plus Therapeutics develops radiotherapeutic drugs for cancer treatment. This chart shows its funding, which at this stage likely comes from grants and clinical research funding rather than commercial sales. It illustrates investments in developing an innovative method for delivering radiation directly to tumors.
Sales of companies in the market segment - Breast cancer
Plus Therapeutics, Inc. develops innovative radiotherapeutic drugs for the treatment of cancer. The company's business is segmented by its key development programs, targeting various tumor types, such as brain cancer. This chart depicts the financial flows associated with one of its lead candidates, highlighting its clinical and commercial potential.
Overall market sales
Plus Therapeutics, Inc. develops radiotherapeutic agents for the treatment of cancer, particularly brain cancer. This innovative technology enables the delivery of radiation directly to the tumor. The company's success depends on the results of clinical trials and exemplifies how advances in nuclear medicine can transform approaches to cancer treatment.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Plus Therapeutics Inc.
Plus Therapeutics is developing targeted radiation therapy for the treatment of difficult-to-treat cancers, particularly recurrent glioblastoma. Future sales projections are based on the expected success of its clinical trials and the potential of its technology to deliver high doses of radiation directly to tumors while minimizing damage to healthy tissue.
%20sales%20of%20the%20company%20Plus%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Plus-Therapeutics-Inc.&v=1772604261269 "Schedule of future (projected) sales of the company Plus Therapeutics Inc.")
Future (projected) sales of companies in the market segment - Breast cancer
Plus Therapeutics develops radiotherapeutic drugs for the treatment of cancer, particularly breast cancer. This chart shows expectations for the oncology sector. It helps understand the potential of innovative radiotherapy methods and the demand analysts predict for new approaches to treating difficult-to-treat tumors.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Breast%20cancer&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Breast-cancer&v=1772604261384 "Schedule of future (projected) sales of companies in the market segment - Breast cancer")
Future (projected) sales of the market as a whole
Plus Therapeutics develops radiotherapeutic drugs for the treatment of cancer. Funding for such cutting-edge and capital-intensive research is highly dependent on market sentiment. This chart of overall sales forecasts reflects economic confidence, which influences investor willingness to invest in the risky biotech sector.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772604261465 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Plus Therapeutics Inc.
Plus Therapeutics, Inc. is developing targeted radiotherapy for the treatment of difficult-to-treat cancers, such as brain cancer. Being in the clinical stage, the company incurs high R&D costs. This chart illustrates the financial picture of an innovative biotech company, where ongoing investments in research are key to the development of future breakthrough treatments.
Market segment marginality - Breast cancer
Plus Therapeutics develops radiotherapeutic drugs for the treatment of cancer, particularly brain cancer. Effectiveness in this complex field depends on the precise delivery of radiation to the tumor and the management of a complex manufacturing process. The chart below compares the company's operating model to other oncology biotechs.
Market marginality as a whole
Plus Therapeutics, Inc. develops radiotherapeutic drugs for the treatment of cancer, particularly recurrent glioblastoma. The company operates in the field of advanced oncology. This chart shows the profitability of mature businesses, while PSTV's value is determined by the potential of its technology to significantly improve the prognosis for patients with difficult-to-treat cancers.
Employees in the company, segment and market as a whole
Number of employees in the company Plus Therapeutics Inc.
Plus Therapeutics develops innovative radiotherapeutic drugs for cancer treatment. This chart shows a team of highly specialized scientists, including radiochemists and oncologists. The size of this team reflects the scale of investment required to advance such complex treatments through clinical trials.
Share of the company's employees Plus Therapeutics Inc. within the market segment - Breast cancer
Plus Therapeutics develops radiotherapeutic drugs for the treatment of cancer, particularly breast cancer. This cutting-edge approach requires a multidisciplinary team of physicists, chemists, and oncologists. This chart shows its human capital investment in creating next-generation radiotherapy agents.
Number of employees in the market segment - Breast cancer
Plus Therapeutics develops radiotherapy drugs for the treatment of cancer, particularly breast cancer. This chart reflects employment in the oncology sector. The growing number of radiation oncology specialists reflects the development of more precise and effective radiation therapy methods, which aligns with Plus Therapeutics' mission.
Number of employees in the market as a whole
Plus Therapeutics develops radiotherapeutic drugs for the treatment of cancer. In this capital-intensive industry, investment and science are key. This chart shows overall employment, but for Plus Therapeutics, successful trial results are the primary driver of funding and team expansion.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Plus Therapeutics Inc. (PSTV)
Plus Therapeutics, Inc. develops radiotherapeutic drugs for cancer treatment. A very high market capitalization per employee is typical for biotech companies in the clinical development stage. This chart shows that investors are investing not in assets, but in the hope of a breakthrough technology being developed by a small group of highly qualified scientists.
%20of%20the%20company%20Plus%20Therapeutics%20Inc.%20(PSTV)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Plus-Therapeutics-Inc.-PSTV&v=1772604261921 "Chart of market capitalization per employee (in thousands of dollars) of the company Plus Therapeutics Inc. (PSTV)")
Market capitalization per employee (in thousands of dollars) in the market segment - Breast cancer
Plus Therapeutics develops radiotherapeutic drugs for the treatment of cancer, including breast cancer. In biopharma, this metric is directly related to the market's assessment of the company's clinical research and technology prospects. It reflects the value each scientist and specialist creates by working on innovative treatments.
%20by%20market%20segment%20-%20Breast%20cancer&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Breast-cancer&v=1772604261949 "Market capitalization per employee (in thousands of dollars) by market segment - Breast cancer")
Market capitalization per employee (in thousands of dollars) for the overall market
Plus Therapeutics, Inc. develops radiotherapeutic drugs for the treatment of difficult-to-treat cancers such as glioblastoma. This is a cutting-edge and complex area of oncology. The chart illustrates the high potential value the market attributes to the scientific team's work on breakthrough treatments.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772604262041 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Plus Therapeutics Inc. (PSTV)
Plus Therapeutics develops innovative cancer treatments using radiation therapy, specifically by delivering isotope-laden nanoparticles directly to tumors (for example, in the brain). It is a clinical-stage R&D company. This negative graph shows how much capital is invested in each scientist and physician working on this complex targeted radiation delivery technology.
%20Chart%20Plus%20Therapeutics%20Inc.%20(PSTV)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Plus-Therapeutics-Inc.-PSTV&v=1772604262098 "Company Profit Per Employee (in thousands of dollars) Chart Plus Therapeutics Inc. (PSTV)")
Profit per employee (in thousands of dollars) in the market segment - Breast cancer
Plus Therapeutics develops radiotherapeutic drugs for the treatment of cancer, particularly breast cancer. This is a high-tech niche where value is created by the scientific team. This metric demonstrates how efficiently their specialists transform complex technologies into financial assets, allowing them to be compared with other biotech companies.
%20in%20the%20market%20segment%20-%20Breast%20cancer&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Breast-cancer&v=1772604262147 "Chart of profit per employee (in thousands of dollars) in the market segment - Breast cancer")
Profit per employee (in thousands of dollars) for the market as a whole
Plus Therapeutics (PSTV) is developing targeted radiotherapy for cancer treatment (for example, brain cancer). It is a clinical-stage biotech company with no commercial revenue. This negative metric reflects the cost of maintaining a top-notch scientific team. It shows investors the investment in personnel working on this complex technology.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772604262171 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Plus Therapeutics Inc. (PSTV)
Plus Therapeutics develops radiotherapeutic drugs for the treatment of cancer. While in the clinical stage, its revenue may be negligible. This chart is an indicator of future potential, revealing whether its innovative technology can be developed into a commercially successful product.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Plus-Therapeutics-Inc.-PSTV&v=1772604262202 "Sales chart per company employee Plus Therapeutics Inc. (PSTV)")
Sales per employee in the market segment - Breast cancer
Plus Therapeutics develops radiotherapeutic drugs for the treatment of difficult-to-treat cancers (such as glioblastoma). They deliver radiation directly to the tumor. This chart compares revenue per employee (R&D) to the industry average. It reflects how productive their innovative drug delivery platform is in the research phase.
Sales per employee for the market as a whole
Plus Therapeutics (PSTV) is a biotech company developing radiopharmaceuticals for the treatment of difficult-to-treat cancers (such as brain cancer). These drugs are in the clinical stage and the company has no commercial sales revenue. This graph would show $0, which is typical for R&D companies whose scientists are focused on clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company Plus Therapeutics Inc. (PSTV)
Plus Therapeutics (PSTV) is developing radionuclide therapy (radiation delivery) for the treatment of hard-to-treat tumors, such as brain cancer. This is an extremely complex and niche area of oncology. This chart shows the number of investors who are skeptical about the chances of success of this technology, its safety, and commercial potential.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Plus-Therapeutics-Inc.-PSTV&v=1772604262460 "Short Shares Chart for the Company Plus Therapeutics Inc. (PSTV)")
Shares shorted by market segment - Breast cancer
Plus Therapeutics (PSTV) develops radiopharmaceuticals for the treatment of difficult-to-treat cancers, particularly glioblastoma (brain cancer). They deliver radiation directly to the tumor. This chart shows the odds against the radiopharmaceutical sector. It reflects market skepticism about this complex technology and the risks associated with the production and delivery of radioactive isotopes.
Shares shorted by the overall market
Plus Therapeutics (PSTV) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Plus Therapeutics Inc. (PSTV)
Plus Therapeutics is developing radiotherapeutic drugs for the treatment of cancer, specifically glioblastoma (brain cancer). It's a clinical-stage biotech. This oscillator measures investor sentiment: it shows when positive trial data leads to "overbought" (above 70) or when delays lead to "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Plus-Therapeutics-Inc.-PSTV&v=1772604262670 "RSI 14 indicator chart for the company's stock Plus Therapeutics Inc. (PSTV)")
RSI 14 Market Segment - Breast cancer
Plus Therapeutics develops radiotherapeutic drugs (radiopharmaceuticals) for the treatment of difficult-to-treat cancers, including brain and breast cancer. This chart measures the collective excitement in the oncology biotech sector. It helps determine whether the entire segment is overheated.
RSI 14 for the overall market
For Plus Therapeutics, a biotech in R&D, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast PSTV (Plus Therapeutics Inc.)
Plus Therapeutics is developing radionuclide therapy, delivering concentrated radiation directly to tumors (e.g., brain cancer). This chart shows the analysts' average forecast. Their targets are based on clinical data, safety, and efficacy of this targeted radiation therapy.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-PSTV-Plus-Therapeutics-Inc.&v=1772604262763 "A chart showing analyst consensus forecasts for the expected stock price. PSTV (Plus Therapeutics Inc.)")
The difference between the consensus estimate and the actual stock price PSTV (Plus Therapeutics Inc.)
Plus Therapeutics is an oncology company developing an innovative platform for delivering radiotherapy (rhenium nanoparticles) directly to brain tumors. This chart shows the difference between the market valuation and the consensus forecast. It highlights the enormous, yet risky, potential analysts see in this targeted therapy.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-PSTV-Plus-Therapeutics-Inc.&v=1772604262766 "A chart showing the difference between the consensus forecast and the actual stock price. PSTV (Plus Therapeutics Inc.)")
Analyst consensus forecast for stock prices by market segment - Breast cancer
Plus Therapeutics is an oncology company developing radiotherapy (based on nanoparticles and rhenium isotopes) for the treatment of brain cancer (glioblastoma). This chart shows general expectations for the breast (and brain) cancer sector. It reflects whether experts believe in a breakthrough in "nuclear medicine" against cancer.
Analysts' consensus forecast for the overall market share price
Plus Therapeutics is a biotech company developing radiopharmaceuticals (radiation-enhanced nanoparticles) that are delivered directly to brain and liver tumors. This chart shows the overall market "risk appetite." For PSTV, which operates in the complex field of nuclear medicine, overall market optimism (risk appetite) is critical for attracting capital for R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Plus Therapeutics Inc.
Plus Therapeutics specializes in nuclear oncology. Their signature technique is delivering a high dose of a radioactive isotope (Rhenium-186) directly to tumors (for example, brain or breast) to destroy them from the inside. This graph is a clear indicator of their faith in R&D. It reflects their progress in clinical trials and their belief in their radioactive approach to cancer treatment.
AKIMA Market Segment Index - Breast cancer
Plus Therapeutics (PSTV) is a biopharmaceutical company developing targeted radiotherapy drugs. Their lead candidate targets recurrent brain cancer (glioblastoma), not just breast cancer. This chart shows the segment average index, helping investors assess how this high-tech therapy for difficult-to-treat cancers compares to the average.
The AKIM Index for the overall market
Plus Therapeutics is a company developing nanoliposomal radiotherapeutic agents for the treatment of rare cancers (glioblastoma, leptomeningeal metastases). This chart, reflecting the market average, provides a macro-background. It helps assess how this innovative local delivery platform compares to overall economic trends.
